New to The Street’s TV Host Jane King from the Nasdaq MarketSite Studio talks with David Luci, the President/CEO of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) (“Company”), a late-stage biopharmaceutical Company. ACXP is developing a new class of small molecular antibiotics for life-threatening bacterial infections. With the successful completion of Phase 2 clinical trials on the Ibezapolstat drug, a treatment for patients with Clostridioides difficile Infections (CDI), management met with the FDA to map out a pathway for a full FDA drug approval. David tells viewers that the meeting was successful and that the FDA and ACXP agreed on a Phase 3 clinical trial protocol. Once fully approved, the Company will have the opportunity to pursue worldwide partnerships and revenue-streaming agreements. Over the next couple of years, David and the ACXP team expect a successful Phase 3 trial with full FDA approval. ACXP believes Ibezapolstat could be a market worth over $1B. As such, its shareholder base and stock prices could greatly benefit once the regulatory agencies in the USA and internationally approve the drug. Clinical data to date on completed trials have shown that the Ibezapolstat drug effectively treats CDI with no reinfections. The on-screen QR code is available during the show; download or visit Acurx Pharmaceuticals, Inc. – https://www.acurxpharma.com/.
To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv
Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet
Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/
About New to the Street: https://newtothestreet.com/
Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list